Industrial wastewater treatment provider Axine Water Technologies has signed a multi-year wastewater services agreement with a leading U.S. pharmaceutical manufacturer.
Under the multi-year agreement, Axine will own, operate, service and maintain a wastewater treatment system at the customer’s manufacturing facility in the Northeastern U.S.
“Axine is establishing a new standard of care in the pharmaceutical industry for on-site treatment of toxic organic pollutants,” says Axine’s CEO Jonathan Rhone. “This application will not only eliminate organic pollutants, it will do so at the lowest cost and the lowest risk while ensuring the highest degree of operational efficiency, safety and compliance. We’re seeing tremendous demand for our solutions across the pharmaceutical industry as manufacturers seek to reduce the cost, risk and environmental impact of toxic organics in wastewater.”
Based on Axine’s electrochemical oxidation technology, the system will treat manufacturing process wastewater contaminated with organic solvents. The treated water will be safely discharged to the local municipal wastewater plant. The customer’s goal of installing the Axine system is to eliminate solvents in wastewater, ensuring the facility meets all local, state and US EPA categorical discharge limits. The agreement follows several months of successful testing and piloting of Axine’s solutions.
The system will be operational in early 2019.
“Canadian clean technology companies are working hard to develop solutions for customers worldwide,” said the Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for Western Economic Diversification Canada. “The Government of Canada is proud to help Axine Water Technologies develop new, sustainable solutions to business challenges faced by pharmaceutical companies and other industries. Organizations like Axine spur innovation, create high-quality jobs and make Canada a leader in technology development.”
